OE欧亿
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2025-05-08
Latest Results of Serplulimab in Gastric Cancer Released at IGCC 2025
2025-04-29
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
2025-04-28
Henlius Receives Clinical Approval in EU for Head-to-Head Phase 3 MRCT of Dual HER2 Blockade Therapy on First-Line HER2+ GC
2025-04-28
Preclinical Results of Henlius’ Multiple Innovative Candidates Debut at AACR 2025
2025-04-25
Henlius Enters Exclusive License Agreement with Lotus for Anti-PD-1 mAb Serplulimab in South Korea
2025-04-24
Henlius to Present Latest Research Results at ASCO 2025
2025-04-17
Henlius' Innovative Anti-HER2 mAb HLX22 in Combination with T-Dxd Advances to a Phase 2 Clinical Trial for the Treatment of HER2-low, HR-positive BC with First Patient Dosed
2025-04-17
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
2025-04-16
Henlius to Present Latest Results of Serplulimab in Gastric Cancer at IGCC 2025
1
2
3
4
